Nuflumic Acid

# Nuflumic acid ## Overview - **Classification**: Non-Steroidal Anti-Inflammatory Drug (NSAID), Fenamate class. - **Mechanism**: Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, leading to reduced prostaglandin synthesis. This provides anti-inflammatory, analgesic, and antipyretic effects. ## Primary Indications 1. **Inflammatory and painful conditions**: Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis. 2. **Musculoskeletal pain**: Sprains, strains, low back pain, tendinitis. 3. **Dysmenorrhea**: Primary painful menstruation. 4. **Post-operative pain**: Mild to moderate pain relief. ## Adult Dosing ### Standard Dosing **Acute Pain / Inflammation** - **Dose**: **250 mg** to **500 mg** - **Frequency**: **2-3 times daily** - **Route**: Oral - **Maximum Dose**: **1500 mg/day**. - **Duration**: Use for the shortest effective duration. **Dysmenorrhea** - **Dose**: **250 mg** - **Frequency**: **3 times daily** - **Route**: Oral - **Duration**: Start at pain onset, continue for 2-3 days. ### Dose Adjustments - **Renal Impairment**: Avoid in **severe renal impairment (CrCl < 30 mL/min)**. Use with caution and reduced doses in moderate impairment; monitor renal function. - **Hepatic Impairment**: Use with caution; start at lower doses. Monitor liver function closely. Avoid in severe hepatic failure. - **Elderly Patients**: Increased risk of GI, renal, and CV adverse effects. Start with the lower end of the dosing range, use for the shortest duration. Monitor closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **Not recommended**. - **Special Notes**: Safety and efficacy are not established. High risk of renal, GI, and cardiovascular complications. ### Infants (1-12 months) - **Dose**: **Not recommended**. - **Special Notes**: Safety and efficacy are not established. Avoid use. ### Children (1-12 years) - **Dose**: **Not recommended** for routine use. - **Special Notes**: Use is generally discouraged due to limited safety data and potential for serious adverse effects. Only consider under specialist supervision for specific indications. ### Adolescents (13-18 years) - **Dose**: May consider adult dosing, **e.g., 250 mg 2-3 times daily**. - **Maximum**: **1000 mg/day** (consider lower end for adolescents). - **Special Notes**: Use for the shortest duration possible. Monitor for GI and renal effects. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to nuflumic acid, aspirin, or other NSAIDs. - **Absolute**: Active gastrointestinal (GI) bleeding or peptic ulcer. - **Absolute**: Severe heart failure (NYHA Class III-IV), severe renal (CrCl < 30 mL/min) or hepatic failure. - **Absolute**: Third trimester of pregnancy. - **Absolute**: History of asthma, urticaria, or allergic reactions to aspirin or NSAIDs. - **Absolute**: Peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. ### Common Adverse Effects - **Very Common (>10%)**: Gastrointestinal upset (nausea, dyspepsia, abdominal pain, diarrhea). - **Common (1-10%)**: Headache, dizziness, skin rash, fluid retention, edema. - **Serious but Rare**: GI perforation/bleeding, acute renal failure, severe cutaneous reactions (SJS/TEN), cardiovascular thrombotic events (MI, stroke), hepatic injury, anaphylaxis. ### Key Drug Interactions - **Anticoagulants (e.g., Warfarin)**: Increased risk of bleeding. Monitor INR closely; adjust anticoagulant dose. - **Corticosteroids, SSRIs**: Increased risk of GI ulceration and bleeding. Co-administer with caution; consider PPI prophylaxis. - **Lithium**: Increased lithium levels due to reduced renal excretion. Monitor serum lithium levels. - **Methotrexate**: Increased methotrexate toxicity (renal). Avoid concomitant use or monitor closely. - **Diuretics, ACE inhibitors, ARBs**: Reduced antihypertensive effect and increased risk of renal impairment. Monitor blood pressure and renal function. ## Monitoring & Follow-up - **Before Treatment**: Complete Blood Count (CBC), renal function (Cr, eGFR), Liver Function Tests (LFTs). - **During Treatment**: - **Short-term**: Monitor for GI symptoms; no routine labs needed unless risk factors. - **Long-term**: Periodically monitor CBC, renal function (e.g., every 3-6 months), LFTs (e.g., every 6-12 months). - **Clinical Signs**: Watch for signs of GI bleeding (tarry stools, hematemesis), peripheral edema, skin rash, or unusual bruising/bleeding. ## Clinical Pearls - 💡 **Tip 1**: Always use the **lowest effective dose** for the **shortest possible duration** to minimize adverse effects. - 💡 **Tip 2**: Advise patients to take with **food or milk** to reduce gastrointestinal upset. - 💡 **Tip 3**: Counsel patients to report signs of **GI bleeding** (e.g., black, tarry stools, persistent abdominal pain) immediately. - 💡 **Tip 4**: Avoid use in patients with a history of **cardiovascular disease** or **GI ulcers** if possible. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.